Noxa/Bcl-2 Protein Interactions Contribute to Bortezomib Resistance in Human Lymphoid Cells

Genome-Wide siRNA Screen for Modulators of Cell Death Induced by Proteasome Inhibitor Bortezomib

(2010) Siquan Chen et al.   CANCER RESEARCH

Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-Mediated Potentiation of Bortezomib-Induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells

(2010) R. Rao et al.   CLINICAL CANCER RESEARCH

Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes

(2010) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma

(2010) L. Paoluzzi et al.   CLINICAL CANCER RESEARCH

Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy

(2010) J. J. Wright   CLINICAL CANCER RESEARCH

Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells

(2010) M. Baou et al.   HAEMATOLOGICA

Perturbation of the Bcl-2 Network and an Induced Noxa/Bcl-xL Interaction Trigger Mitochondrial Dysfunction after DNA Damage

(2010) Hernando Lopez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Anti-apoptotic Protein BCL2L1/Bcl-xL Is Neutralized by Pro-apoptotic PMAIP1/Noxa in Neuroblastoma, Thereby Determining Bortezomib Sensitivity Independent of Prosurvival MCL1 Expression

(2010) Judith Hagenbuchner et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

BH3 Domains other than Bim and Bid Can Directly Activate Bax/Bak

(2010) Han Du et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex

(2010) Alan D. Brooks et al.   MOLECULAR CANCER RESEARCH

The BCL-2 Family Reunion

(2010) Jerry E. Chipuk et al.   MOLECULAR CELL

BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program

(2010) D. Ren et al.   SCIENCE

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

(2009) N. Di Bella et al.   BLOOD

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

(2009) John Gerecitano et al.   BRITISH JOURNAL OF HAEMATOLOGY

Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis

(2009) E M Michalak et al.   CELL DEATH AND DIFFERENTIATION

A phase II study of bortezomib in patients with MALT lymphoma

(2009) M. Troch et al.   HAEMATOLOGICA

Protein Kinase Cβ Modulates Ligand-induced Cell Surface Death Receptor Accumulation

(2009) Xue Wei Meng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Context-dependent Bcl-2/Bak Interactions Regulate Lymphoid Cell Apoptosis

(2009) Haiming Dai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cell Death

(2009) Richard S. Hotchkiss et al.   NEW ENGLAND JOURNAL OF MEDICINE

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

(2008) J. E. Karp et al.   BLOOD

IFN-  and Bortezomib Overcome Bcl-2 and Mcl-1 Overexpression in Melanoma Cells by Stimulating the Extrinsic Pathway of Apoptosis

(2008) G. B. Lesinski et al.   CANCER RESEARCH

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-xL Inhibitor, ABT-737

(2008) K. Okumura et al.   CLINICAL CANCER RESEARCH

Mechanisms of proteasome inhibitor action and resistance in cancer

(2008) David J. McConkey et al.   DRUG RESISTANCE UPDATES

Bortezomib in mantle cell lymphoma

(2008) K Stephen Suh et al.   Future Oncology

Bortezomib: Putting mantle cell lymphoma on death row

(2008) Andrew H. Wei et al.   LEUKEMIA & LYMPHOMA

Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region

(2008) K. Kandasamy et al.   MOLECULAR CANCER THERAPEUTICS

BCL-2 family antagonists for cancer therapy

(2008) Guillaume Lessene et al.   NATURE REVIEWS DRUG DISCOVERY

How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?

(2008) Jerry E. Chipuk et al.   TRENDS IN CELL BIOLOGY

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY